VolitionRx Limited prepaid in cash approximately $422,000 on September 11, 2026, satisfying the outstanding balance of its senior secured convertible promissory note originally issued for $7,500,000 to Lind Global Asset Management XII LLC. This early retirement eliminates potential future equity dilution associated with the conversion of the 2025 Note. The company's second note to Lind, originally $2,400,000, remains outstanding with a balance of approximately $2,041,667. VolitionRx Limited is a multinational epigenetics company developing and commercializing blood tests for early disease detection and monitoring.
